How Has TALAPRO-2 Changed the Standard of Care for First-Line mCRPC With HRR Mutations?

In the third part of this peer-to-peer discussion at the 2023 Uromigos Live & Unplugged event, Tanya Dorff, MD, City of Hope, and Neeraj Agarwal, MD, University of Utah, provide an overview of the standard of care for first-line metastatic castration-resistant prostate cancer prior to TALAPRO-2.

They then expound on how the standard of care has since changed and what kind of patients were considered for the TALAPRO-2 study.

View the other parts of this discussion, including Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset Analyses, TALAPRO-2: Toxicities and Treatment Duration, and Importance of Genomic Testing for Patients With Metastatic Prostate Cancer.